ArticleFrontiers in pediatrics2025
Case Report: Nystagmus as a core presenting sign in pediatric anti-Ma2 antibody-associated cerebellar ataxia: diagnostic implications from clinical and serological profiling.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The anti-Ma2 antibody is a well-known, specific marker of paraneoplastic limbic and brainstem encephalitis, mainly described in adult, especially in males with testicular germ cell tumor. Pediatric cases remain exceptionally rare. We present a child with anti-Ma2 antibody-associated cerebellar ataxia in whom nystagmus was identified as a core presenting symptom; the diagnosis was confirmed via cell-based assay (CBA). Case presentation: An 11-year-old boy sought medical attention for symptoms such as vomiting, nystagmus, dizziness, slurred speech, and limb weakness. Routine laboratory tests and brain MRI were normal, simultaneously we ruled out infectious factors. Further limb coordination tests suggested the boy may have cerebellar ataxia. Based on clinical symptoms and the above tests, the boy underwent a comprehensive examination for suspected paraneoplastic neurological syndrome (PNS). Serum enzyme-linked immunospot test was positive (+) for anti-Ma2 antibodies and confirmed by CBA with a titer of 1:10. The boy was diagnosed with anti-Ma2 antibody-associated cerebellar ataxia. Subsequently, he received intravenous immunoglobulin (IVIG) and methylprednisolone (mPD) treatment and experienced significant symptomatic improvement. Complete resolution occurred by 38 days post-discharge, sustained through one-year follow-up. Conclusions: Nystagmus was first identified in pediatric patients with anti-Ma2 antibody-associated syndrome, expanding clinicians' knowledge of the phenotype in children. Our case demonstrates that IVIG and steroids induced rapid and sustained remission despite presumed cell-mediated immunity cases, with complete symptom resolution within 8 weeks and no recurrence at 1-year follow-up. We also emphasize CBA's superior accessibility and its higher sensitivity and specificity in detecting low-titer antibodies for detecting antibodies in autoimmune encephalitis, particularly in mild or atypical presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.